Brief: Kleo Pharmaceuticals Announces CD38 Targeting Antibody Recruiting Molecule To Treat Multiple Myeloma
18/06/2019 12:39
June 18 (Reuters) - Kleo Pharmaceuticals:
* KLEO PHARMACEUTICALS ANNOUNCES A CD38 TARGETING ANTIBODY
RECRUITING MOLECULE (ARM™) TO TREAT MULTIPLE MYELOMA AS THE
FIRST CLINICAL CANDIDATE IN ITS PARTNERSHIP WITH PEPTIDREAM
* KLEO PHARMACEUTICALS - ANTICIPATED HUMAN STUDIES TO
COMMENCE IN
2020.
Source text for Eikon: ID:nPnb7v689a
Further company coverage: 4587.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner